Your AI-Trained Oncology Knowledge Connection!

A New Wave of Progress in the Treatment of Renal Cell Carcinoma: Highlights from ASCO GU 2023 and Beyond : Episode 3

Video

March 23, 2023

Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER

Author(s):

Kathryn E. Beckermann, MD, PhD,Moshe Ornstein, MD, MA

Drs Moshe Ornstein and Mehmet Asim Bilen review updated data from the CheckMate 9ER and CLEAR trials investigating combination treatments for metastatic renal cell carcinoma.

EP: 1.Risk Stratification of Patients with Metastatic Renal Cell Carcinoma (RCC)

EP: 2.Patient Profile Presentation: A 65-Year-Old Woman With Metastatic RCC

Now Viewing

EP: 3.Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER

EP: 4.Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC

EP: 5.Factoring Quality-of-Life, Liver Metastases, and Brain Metastases into Treatment Decision-Making for RCC

EP: 6.Treatment Approaches for Patients with RCC and Bone Metastases

EP: 7.Novel Doublet Combination Therapies in First-Line Metastatic RCC Treatment

EP: 8.Reviewing Data in Frontline Metastatic RCC Treatment from the COSMIC-313 Trial

EP: 9.Updates in the Adjuvant Treatment of Metastatic RCC

EP: 10.Patient Profile Presentation: A 47-Year-Old Male With Refractory RCC

EP: 11.Preferred Treatment Regimens for Refractory RCC

EP: 12.Best Approaches and Emerging Data in the Treatment of Non-Clear Cell RCC

EP: 13.Genetic Counseling for Patients with Non-Clear Cell RCC

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity

Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity

Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity

Latest Conference Coverage

Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

Application of Real-World Evidence in Selecting CAR T in R/R MM

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT

Apalutamide Boosts 24-Month OS in Real-World Population With Metastatic Castration-Sensitive Prostate Cancer

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER

EP: 1.Risk Stratification of Patients with Metastatic Renal Cell Carcinoma (RCC)

EP: 2.Patient Profile Presentation: A 65-Year-Old Woman With Metastatic RCC

EP: 3.Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER

EP: 4.Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC

EP: 5.Factoring Quality-of-Life, Liver Metastases, and Brain Metastases into Treatment Decision-Making for RCC

EP: 6.Treatment Approaches for Patients with RCC and Bone Metastases

EP: 7.Novel Doublet Combination Therapies in First-Line Metastatic RCC Treatment

EP: 8.Reviewing Data in Frontline Metastatic RCC Treatment from the COSMIC-313 Trial

EP: 9.Updates in the Adjuvant Treatment of Metastatic RCC

EP: 10.Patient Profile Presentation: A 47-Year-Old Male With Refractory RCC

EP: 11.Preferred Treatment Regimens for Refractory RCC

EP: 12.Best Approaches and Emerging Data in the Treatment of Non-Clear Cell RCC

EP: 13.Genetic Counseling for Patients with Non-Clear Cell RCC

Newsletter

Latest CME

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Latest Conference Coverage